What Is KPV? Benefits, Research & Safety
An anti-inflammatory tripeptide derived from alpha-MSH, researched for potent NF-κB inhibition and applications in gut and skin inflammation.
UK summary: Not a licensed UK medicine. Tripeptide fragment of alpha-MSH with anti-inflammatory activity in animal IBD / colitis models. No human therapeutic use; UK IBD pathways do not include KPV.
Quick Facts
Overview
KPV — evidence and risk at a glance
Twenty standard modules scored against the Peptide Authority evidence grading methodology. Missing modules indicate the field has not yet been characterised editorially — treat absences as uncertainty rather than reassurance.
01Evidence snapshot
Not a licensed UK medicine. Tripeptide fragment of alpha-MSH with anti-inflammatory activity in animal IBD / colitis models. No human therapeutic use; UK IBD pathways do not include KPV.
02Human evidence grade
03Preclinical evidence grade
04Regulatory status
- UK: Unregulated research peptide. Not approved for human therapeutic use by the MHRA.
- EU: Not approved by the EMA. Available as a research compound.
- Notes: KPV is not approved for therapeutic use in any major jurisdiction. Research use only.
05Approved medical uses
None in the UK or EU as a finished medicine. (Or: not yet documented; treat as absence rather than approval.)
06Unapproved / promotional claims
- Treats inflammatory bowel disease (Crohn's, ulcerative colitis).
- Heals leaky gut and food sensitivities.
- Treats psoriasis and eczema topically.
- Safe oral peptide with no side effects.
07Common internet claims
- Marketed by 'functional medicine' practitioners for gut healing.
- Sold by online retailers in oral capsule and topical formats.
- Promoted as a natural anti-inflammatory tripeptide.
08Claim vs evidence
| Claim | Evidence | Human evidence? | Regulatory concern | Safer wording |
|---|---|---|---|---|
| “Cures IBD / Crohn's / ulcerative colitis” | D | No | High | Animal-model anti-inflammatory effects; no UK-licensed indication; established IBD treatments have decades of human evidence. |
| “Heals leaky gut” | E | No | High | ‘Leaky gut’ is not a recognised UK clinical diagnosis in the form usually marketed; KPV is not a licensed treatment for any GI condition. |
09Safety uncertainty score
Safety profile partly characterised; some signals from observational or preclinical data.
10Known adverse signals
- Limited systematic safety data in humans.
- Theoretical risk of suppressing helpful immune responses.
- Unknown effects when used with biologics or immunosuppressants.
- Topical preparation quality (compounding) unverified.
11Drug-interaction uncertainty
Some interaction data published; check with a prescriber for your specific medicines.
12Anti-doping status
13UK legal position
Unregulated research peptide. Not approved for human therapeutic use by the MHRA.
14EU legal position
Not approved by the EMA. Available as a research compound.
15What this page cannot tell you
- Whether a UK-purchased KPV product contains the tripeptide at the labelled concentration.
- Whether oral administration produces meaningful systemic exposure.
- How it interacts with biologics (anti-TNF) or steroids used in IBD.
- Whether the anti-inflammatory effect translates from cell culture to clinical disease.
16Last reviewed
17Citation quality score
18Research gaps
- No registered Phase 2 or 3 trials for IBD or any human condition.
- Pharmacokinetic data in humans absent.
- Long-term safety unstudied.
- Combination safety with licensed IBD treatments uncharacterised.
19Safer alternatives / established care pathways
- GP and gastroenterology referral for any persistent GI symptoms.
- NHS IBD pathway — anti-TNF biologics, mesalazine, steroids — all with extensive evidence.
- Dermatology referral for psoriasis or eczema, with licensed topical and biologic options.
20Doctor discussion prompts
Questions to ask a qualified clinician
These are starter questions you can adapt for a GP, specialist, pharmacist, or anti-doping advisor. The aim is to help you have a better-informed conversation — not to replace one.
- Is KPV a licensed UK medicine for IBD?
- What licensed IBD or GI treatments should I consider first?
- Should my GI symptoms be properly investigated?
Discovery & History
Mechanism of Action
Researched Benefits
Based on preclinical and clinical research findings:
- 1Potent NF-κB inhibition reducing inflammatory gene expression
- 2Suppression of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6)
- 3Potential applications in inflammatory bowel disease (colitis models)
- 4Anti-inflammatory effects in skin inflammation models
- 5Small size enabling oral and topical delivery possibilities
- 6Anti-inflammatory activity without melanogenic side effects
Claim vs Evidence
How popular claims about KPV stack up against the current research, graded using our public evidence grading methodology.
| Claim | Evidence | Human evidence? | Regulatory concern | Safer wording |
|---|---|---|---|---|
| “Cures IBD / Crohn's / ulcerative colitis” | D | No | High | Animal-model anti-inflammatory effects; no UK-licensed indication; established IBD treatments have decades of human evidence. |
| “Heals leaky gut” | E | No | High | ‘Leaky gut’ is not a recognised UK clinical diagnosis in the form usually marketed; KPV is not a licensed treatment for any GI condition. |
Theoretical Dosing & Protocols
| Theoretical Dosage | Research protocols vary; oral and injectable routes studied |
| Frequency | Daily administration in most research protocols |
| Duration | Typically 2-4 weeks in preclinical studies |
| Notes | Nanoparticle formulations studied for targeted gut delivery. No established human dosing protocols exist. |
Administration Routes
Routes studied in research settings (educational only):
- Subcutaneous injection
- Oral (research)
- Topical (research)
- Nanoparticle delivery (research)
| Half-Life | Stability |
|---|---|
| Short half-life typical of small peptides; exact pharmacokinetic data limited | Relatively stable for a tripeptide; lyophilised form recommended for storage |
Safety Profile & Known Risks
Commonly Reported Side Effects
- Injection site reactions (injectable route)
- Limited human safety data available
Rare Risks & Concerns
- Unknown long-term effects
- Potential immune suppression with chronic use
Contraindications
- Active infections (theoretical)
- Immunocompromised states
- Pregnancy and breastfeeding
UK & EU Regulatory Context
🇬🇧 United Kingdom
Unregulated research peptide. Not approved for human therapeutic use by the MHRA.
🇪🇺 European Union
Not approved by the EMA. Available as a research compound.
Clinical Studies Summary
KPV Anti-Inflammatory Activity in Colitis Models
Preclinical research demonstrated that KPV significantly reduced intestinal inflammation in colitis models, decreasing pro-inflammatory cytokine production and improving mucosal barrier integrity through NF-κB inhibition.
Nanoparticle-Delivered KPV for IBD
Studies explored hyaluronic acid-functionalised nanoparticles loaded with KPV for targeted delivery to inflamed colonic tissue, showing enhanced therapeutic efficacy compared to free KPV in animal models.
Looking for KPV?
Source research-grade KPV from a trusted UK supplier — third-party tested with certificate of analysis.
View at SupplierFrequently Asked Questions
Questions to ask a qualified clinician about KPV
These are starter questions you can adapt for a GP, specialist, pharmacist, or anti-doping advisor. The aim is to help you have a better-informed conversation — not to replace one.
- Is KPV a licensed UK medicine for IBD?
- What licensed IBD or GI treatments should I consider first?
- Should my GI symptoms be properly investigated?
UK regulatory & safety context
Related Research Guides
Related Peptides
BPC-157
A pentadecapeptide derived from human gastric juice, extensively researched for its potential tissue repair and regenerative properties across multiple organ systems.
Learn moreThymosin Alpha-1
A thymic peptide with potent immunomodulatory properties, approved in some countries for treating viral hepatitis and as an immune adjuvant.
Learn moreLL-37
The only human cathelicidin antimicrobial peptide, with broad-spectrum antimicrobial activity and important immunomodulatory functions.
Learn moreVIP
A neuropeptide with vasodilatory, anti-inflammatory, and immunomodulatory properties, researched for various therapeutic applications.
Learn moreAlpha-MSH
A melanocortin peptide with pigmentation, anti-inflammatory, and appetite-regulating effects, the natural basis for several therapeutic developments.
Learn more